Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icodextrin - Innovata/Takeda

Drug Profile

Icodextrin - Innovata/Takeda

Alternative Names: Adept®; Extraneal; Icodextrin solution; Icodial®

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovata
  • Developer Baxter Healthcare Corporation; Takeda
  • Class Glucans; Hexoses
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kidney disorders
  • No development reported Heart failure; Hypertriglyceridaemia

Most Recent Events

  • 14 Apr 2021 No development reported - Phase-II for Hypertriglyceridaemia (In the elderly, In adults) in South Korea (Intraperitoneal)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 11 Oct 2018 Clinical development is ongoing in Hypertriglyceridaemia (In adults, In the elderly) in South Korea (Intraperitoneal) (NCT02166359)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top